Seres TherapeuticsCambridge, Massachusetts, United States
Seres Therapeutics (Employee, Shareholder)
19 - The Impact of Investigational Purified Microbiome Therapeutic SER-109 on Health-Related Quality of Life (HRQoL) of Patients with Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III, a Placebo-Controlled Clinical Trial
On Demand
LB15 - SER-109, an Investigational Microbiome Therapeutic, Reduces Abundance of Antimicrobial Resistance Genes in Patients with Recurrent Clostridioides difficile Infection (rCDI) after Standard-of-Care Antibiotics
Saturday, October 2, 20211:15 PM - 3:00 PM EDT
